Charles River Laboratories International Statistics
Share Statistics
Charles River Laboratories International has 51.14M shares outstanding. The number of shares has increased by 0.7% in one year.
| Shares Outstanding | 51.14M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.23% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 50.59M |
| Failed to Deliver (FTD) Shares | 28 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 1.85M, so 3.62% of the outstanding shares have been sold short.
| Short Interest | 1.85M |
| Short % of Shares Out | 3.62% |
| Short % of Float | 3.66% |
| Short Ratio (days to cover) | 2.73 |
Valuation Ratios
The PE ratio is 25.52 and the forward PE ratio is 21.01. Charles River Laboratories International 's PEG ratio is 4.73.
| PE Ratio | 25.52 |
| Forward PE | 21.01 |
| PS Ratio | 2.93 |
| Forward PS | 2.4 |
| PB Ratio | 3.37 |
| P/FCF Ratio | 33.14 |
| PEG Ratio | 4.73 |
Enterprise Valuation
Charles River Laboratories International Inc. has an Enterprise Value (EV) of 14.90B.
| EV / Earnings | 31.39 |
| EV / Sales | 3.61 |
| EV / EBITDA | 14.44 |
| EV / EBIT | 24.14 |
| EV / FCF | 40.78 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.85.
| Current Ratio | 1.52 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.85 |
| Total Debt / Capitalization | 46.02 |
| Cash Flow / Debt | 0.22 |
| Interest Coverage | 4.52 |
Financial Efficiency
Return on equity (ROE) is 0.13% and return on capital (ROIC) is 7.58%.
| Return on Equity (ROE) | 0.13% |
| Return on Assets (ROA) | 0.06% |
| Return on Capital (ROIC) | 7.58% |
| Revenue Per Employee | 202.42K |
| Profits Per Employee | 23.27K |
| Employee Count | 20.40K |
| Asset Turnover | 0.5 |
| Inventory Turnover | 6.91 |
Taxes
| Income Tax | 100.91M |
| Effective Tax Rate | 0.17 |
Stock Price Statistics
The stock price has increased by -17.55% in the last 52 weeks. The beta is 1.38, so Charles River Laboratories International 's price volatility has been higher than the market average.
| Beta | 1.38 |
| 52-Week Price Change | -17.55% |
| 50-Day Moving Average | 194.16 |
| 200-Day Moving Average | 216.16 |
| Relative Strength Index (RSI) | 47.99 |
| Average Volume (20 Days) | 699.27K |
Income Statement
In the last 12 months, Charles River Laboratories International had revenue of $4.13B and earned $474.62M in profits. Earnings per share was $9.27.
| Revenue | 4.13B |
| Gross Profit | 1.50B |
| Operating Income | 617.26M |
| Net Income | 474.62M |
| EBITDA | 1.03B |
| EBIT | 617.26M |
| Earnings Per Share (EPS) | 9.27 |
Balance Sheet
The company has $276.77M in cash and $3.07B in debt, giving a net cash position of -$2.79B.
| Cash & Cash Equivalents | 276.77M |
| Total Debt | 3.07B |
| Net Cash | -2.79B |
| Retained Earnings | 1.89B |
| Total Assets | 8.00B |
| Working Capital | 482.50M |
Cash Flow
In the last 12 months, operating cash flow was $683.90M and capital expenditures -$318.53M, giving a free cash flow of $365.37M.
| Operating Cash Flow | 683.90M |
| Capital Expenditures | -318.53M |
| Free Cash Flow | 365.37M |
| FCF Per Share | 7.13 |
Margins
Gross margin is 36.39%, with operating and profit margins of 14.95% and 11.49%.
| Gross Margin | 36.39% |
| Operating Margin | 14.95% |
| Pretax Margin | 14.08% |
| Profit Margin | 11.49% |
| EBITDA Margin | 24.99% |
| EBIT Margin | 14.95% |
| FCF Margin | 8.85% |
Dividends & Yields
CRL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 4.87% |
| FCF Yield | 3.75% |
Analyst Forecast
The average price target for CRL is $210, which is 10.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $210 |
| Price Target Difference | 10.4% |
| Analyst Consensus | Hold |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 2.65 |
| Piotroski F-Score | 6 |